Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease

Clinical Biochemistry

Volumn 45, Issue 9, 2012, Pages 655-658

  Eren, Fatih ^a   Kurt, Ramazan ^a   Ermis, Fatih ^b   Atug, Ozlen ^a   Imeryuz, Nese ^a   Yilmaz, Yusuf ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b ISPARTA STATE HOSPITAL   (Turkey)

Author keywords

Enzyme linked immunosorbent assay; Fibroblast growth factor 19; Hepatocyte ballooning; Nonalcoholic fatty liver disease

Indexed keywords

FIBROBLAST GROWTH FACTOR 19;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PILOT STUDY; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX;

EID: 84861230343     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.03.019     Document Type: Article

References (30)

1. Erickson S.K. Nonalcoholic fatty liver disease. J Lipid Res 2009, 50:S412-S416.
2. Sass D.A., Chang P., Chopra K.B. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005, 50:171-180.
3. Almeda-Valdés P., Cuevas-Ramos D., Aguilar-Salinas C.A. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009, 8:S18-S24.
4. Brunt E.M., Tiniakos D.G. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010, 16:5286-5296.
5. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
6. Tilg H., Moschen A.R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008, 19:371-379.
7. Polyzos S.A., Kountouras J., Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009, 9:299-314.
8. Grønbaek H., Thomsen K.L., Rungby J., Schmitz O., Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol 2008, 2:705-711.
9. Bhatnagar S., Damron H.A., Hillgartner F.B. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009, 284:10023-10033.
10. Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J 2008, 55:23-31.
11. Tomlinson E., Fu L., John L., Hultgren B., Huang X., Renz M., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
12. Fu L., John L.M., Adams S.H., Yu X.X., Tomlinson E., Renz M., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603.
13. Zweers S.J., Booij K.A., Komuta M., Roskams T., Gouma D.J., Jansen P.L., et al. The human gallbladder secretes fibroblast growth factor 19 (FGF19) into bile: towards defining the role of FGF19 in the enterobiliary tract. Hepatology 2012, 55:575-583.
14. Stejskal D., Karpísek M., Hanulová Z., Stejskal P. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest 2008, 68:501-507.
15. Kir S., Beddow S.A., Samuel V.T., Miller P., Previs S.F., Suino-Powell K., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011, 331:1621-1624.
16. Yilmaz Y., Yonal O., Kurt R., Alahdab Y.O., Ozdogan O., Celikel C.A., et al. Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. Arch Med Res 2011, 42:38-43.
17. Yilmaz Y., Eren F., Ayyildiz T., Colak Y., Kurt R., Senates E., et al. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clin Chim Acta 2011, 412:2296-2299.
18. Senates E., Yilmaz Y., Colak Y., Ozturk O., Altunoz M.E., Kurt R., et al. Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2011, 9:287-290.
19. ACE/ADA Task Force on Inpatient Diabetes American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006, 29:1955-1962.
20. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C., American Heart Association, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
21. Schreuder T.C., Marsman H.A., Lenicek M., van Werven J.R., Nederveen A.J., Jansen P.L., et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010, 298:G440-G445.
22. Barutcuoglu B., Basol G., Cakir Y., Cetinkalp S., Parildar Z., Kabaroglu C., et al. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 2011, 41:390-396.
23. Wu X., Ge H., Lemon B., Vonderfecht S., Weiszmann J., Hecht R., et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010, 285:5165-5170.
24. Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. Expert Rev Gastroenterol Hepatol 2011, 5:223-231.
25. Sawey E.T., Chanrion M., Cai C., Wu G., Zhang J., Zender L., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011, 19:347-358.
26. Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007, 13:837-844.
27. Miyata M., Sakaida Y., Matsuzawa H., Yoshinari K., Yamazoe Y. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol Pharm Bull 2011, 34:1885-1889.
28. Emanuele E. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008, 48:2086-2087.
29. Yilmaz Y., Ulukaya E. Toward a biochemical diagnosis of NASH: insights from pathophysiology for distinguishing simple steatosis from steatohepatitis. Curr Med Chem 2011, 18:725-732.
30. Vuppalanchi R., Unalp A., Van Natta M.L., Cummings O.W., Sandrasegaran K.E., Hameed T., et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:481-486.